BTIG downgraded Outlook Therapeutics (OTLK) to Neutral from Buy with no price target While the firm believes Lytenava has inherent benefits over compounded bevacizumab in wet age-related macular degeneration, it needs to see confirmation of a clear path to potential approval in the U.S. and/or signs of commercial momentum in Europe in order to get more constructive, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics reports Q2 adjusted EPS (16c), consensus (12c)
- Outlook Therapeutics Launches New $100M ATM Offering
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/11/26?
- Outlook Therapeutics Announces New Equity Financing Transaction